San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Bright Peak Therapeutics is raising $106,500,011.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Fredrik Wiklund played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bright Peak Therapeutics
At Bright Peak we are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties. Using our proprietary Enhanced Design and Combine (EDC) chemistry platform, we are developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases. Bright Peak’s chemistry know-how originated in the laboratory of co-founder Jeffrey Bode, Ph.D., and is exclusively licensed to the company. Dr. Bode is a professor of organic chemistry at ETH Zürich and a leader in the chemical synthesis of proteins. Over the last decade his research group has developed and optimized pioneering approaches to synthesizing and tailoring proteins with atomic precision, creating unique constructs for controlling biological pathways in cancer immunotherapy and autoimmune diseases. Initially seeded and launched by Versant Ventures at the firm’s Ridgeline Discovery laboratories, Bright Peak is co-located in Basel, Switzerland and San Diego, California.

To learn more about Bright Peak Therapeutics, visit http://brightpeaktx.com/

Contact:
Fredrik Wiklund, Chief Executive Officer
949-326-6604
https://www.linkedin.com/in/fred-wiklund-43361551/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved